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Abstract: Zonisamide is a modern antiepileptic drug (AED) that is distinguished from other 
AEDs by its unique structure and broad mechanistic proﬁ  le. Preclinical studies have reported 
a range of potential mechanisms of action for zonisamide, such as blocking voltage-gated 
sodium channels, reduction of T-type calcium channel currents, and enhancement of gamma-
aminobutyric acid (GABA)-mediated inhibition, which are indicative of its broad antiseizure 
effects. Zonisamide has a favorable linear pharmacokinetic proﬁ  le, a long half-life, and a low 
incidence of protein-binding interactions with other AEDs. Hepatically metabolized through 
the cytochrome P450 pathway, zonisamide does not induce its own metabolism or liver 
enzymes. For more than 2 decades, zonisamide has been extensively used as monotherapy 
and adjunctive therapy for the treatment of partial and generalized seizures in pediatric and 
adult patients in Japan. Zonisamide was approved in the USA in 2000 as adjunctive therapy 
for partial seizures in adults. With over 2 million patient-years of exposure internationally, 
zonisamide has demonstrated safety and efﬁ  cacy against a multitude of epilepsy and seizure 
types, including both partial and generalized seizures. This review focuses on the experience 
and use of zonisamide in partial seizures, as well as possible new uses for zonisamide.
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History of zonisamide
Zonisamide (Zonegran®; Eisai Inc, Teaneck, NJ, USA) is a newer, broad-spectrum 
antiepileptic drug (AED) that has been shown to be effective in the treatment of 
refractory partial seizures (Schmidt et al 1993; Faught et al 2001; Sackellares et al 
2004). Chemically classiﬁ  ed as a sulfonamide (Figure 1), zonisamide is character-
ized by a unique structural, mechanistic, and pharmacokinetic proﬁ  le that is distinct 
from that of other AEDs. Zonisamide is a benzisoxazole derivative, originally 
synthesized in Japan in 1974 during exploratory research on psychiatric drugs, 
where it was subsequently identiﬁ  ed as having anticonvulsant activity during 
screening (Seino 2004). Preclinical animal studies conducted in Japan revealed 
the antiseizure effects of zonisamide on maximal electroshock-induced seizures 
in rats, mice, rabbits, and dogs. In these animal models, zonisamide exhibited 
a wider therapeutic plasma concentration range compared with phenytoin and 
carbamazepine (Masuda et al 1979).
In 1979, zonisamide was evaluated in Phase I clinical trials at the National 
Epilepsy Center in Japan, where it was observed to have a long elimination half-life 
and good tolerability in a healthy male population. Phase II clinical trials were 
initiated in 1985 and were followed by Phase III trials. With over 1000 zonisamide-
treated patients, the Japanese Phase II and Phase III trials showed that zonisamide 
was effective against simple and complex partial seizures, partial seizures with 
secondary generalization, and select generalized seizures (eg, tonic-clonic). In addi-
tion, zonisamide as monotherapy was effective in these trials, with 72% of patients Neuropsychiatric Disease and Treatment 2006:2(3) 270
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experiencing greater than 50% seizure reduction compared 
with baseline. In these trials, zonisamide was shown to be either 
superior or equivalent in efﬁ  cacy and safety to existing AEDs. 
Adverse events (AEs) observed with zonisamide included 
drowsiness, ataxia, and loss of appetite (Seino 2004).
With promising results from the animal and clinical 
studies, zonisamide was approved in Japan in 1989 as both 
monotherapy and adjunctive therapy for children and adults 
with generalized or partial seizures. Zonisamide was later 
marketed for the same indication in South Korea in June 1992 
(Seino 2004). Several controlled clinical studies conducted in 
the USA and Europe further demonstrated zonisamide’s efﬁ  -
cacy in the treatment of partial seizures in adults. Zonisamide 
was approved in 2000 in the USA as adjunctive therapy in the 
treatment of partial seizures in adults with epilepsy (Schmidt 
et al 1993; Faught et al 2001; Sackellares et al 2004). Cur-
rently, clinical experience with zonisamide has yielded a 
conservative approximation of 2 million patient-years of 
exposure worldwide (Brodie et al 2005).
Mechanism of action
Although the precise molecular mechanisms behind the 
antiseizure activity of zonisamide are unknown, zonisamide 
has demonstrated a broad mechanistic proﬁ  le in animal 
models. Zonisamide is thought to act through its blocking 
of voltage-dependent sodium channels, reduction of voltage-
dependent T-type inward calcium currents, binding to the 
gamma-aminobutyric acid (GABA)–benzodiazepine recep-
tor complex, and facilitation of both dopaminergic and 
serotonergic neurotransmission, as summarized in Table 1. 
Although zonisamide exhibits weak carbonic anhydrase 
inhibition, this is not considered a primary mechanism of 
action in its antiseizure activity.
Block of selected voltage-gated 
ion channels
The antiepileptic effects of zonisamide on generalized 
tonic-clonic and partial seizures are believed to stem from 
the modulation of voltage-gated sodium channels. In an in 
vitro study using Myxicola giant axons and in another study 
of cultured mouse spinal cord neurons, zonisamide was 
shown to reduce high-frequency repetitive ﬁ  ring via a block 
of voltage-gated sodium channels (Schauf 1987; Rock et al 
1989). Other AEDs, including phenytoin, lamotrigine, and 
carbamazepine, also exhibit this mechanism of action (White 
1999; Rogawski and Loscher 2004). In other animal studies, 
zonisamide was shown to block low-voltage gated T-type 
calcium channels (Suzuki et al 1992; Kito et al 1996). T-type 
calcium channels are thought to regulate neuronal ﬁ  ring 
and play a role in childhood absence epilepsy, and may also 
account for some of zonisamide’s antiseizure effect against 
catastrophic childhood epilepsy (White 1999; Rogawski and 
Loscher 2004).
Enhancement of GABA
Kawai and colleagues (1994) showed that zonisamide 
enhances the release of GABA from slices of mouse hip-
pocampus. These results suggest that elevations of GABA 
levels in the brain and increases in GABA-mediated inhi-
bition may be associated with the antiseizure activity of 
zonisamide (Kawai et al 1994). Ueda et al (2003) showed 
that zonisamide could also increase extracellular GABA 
by the up-regulation of a neuronal glutamate transporter 
(ie, EAAC-1) and a decreased production of the GABA 
transporter (ie, GAT-1) in the rat hippocampus and frontal 
cortex. The altered expression of the rat glutamate–GABA 
transporters and increase in extracellular GABA may 
enhance GABA’s inhibitory effect during seizures (Ueda 
et al 2003). Hence, it appears that zonisamide can increase 
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Figure 1 Chemical structure of zonisamide.
Table 1 Potential mechanisms of action and effects of zonisamide
Potential mechanism of action Potential effect
Block of voltage-gated sodium
channels
Reduction in generalized tonic-
clonic and partial seizures
Block of voltage-gated T-type
calcium channels
Reduction in absence seizures
Increase in extracellular GABA Increase in GABA-mediated 
inhibition of seizures
Reduction in extracellular
glutamate
Reduction in seizure activity
initiated by extracellular glutamate
Serotonergic interactions Reduction in seizure activity and/or 
an increase in positive
psychotropic effects
Dopaminergic interactions Reduction in seizure activity and/or 
an increase in positive
psychotropic effects
Free radical scavenging Neuroprotective effect
Abbreviations: GABA, gamma-aminobutyric acid.Neuropsychiatric Disease and Treatment 2006:2(3) 271
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GABA-mediated inhibition through two distinct molecular 
mechanisms, a primary and secondary mechanism.
Block of glutamate neurotransmission
The effects of zonisamide on neurotransmission and intra-
cellular calcium have been evaluated in several preclinical 
studies. Results from these studies suggest that zonisamide 
reduces calcium-dependent, potassium-evoked extracellular 
glutamate release in the hippocampus (Okada et al 1998; 
Zhu and Rogawski 1999). Since glutamate is an excitatory 
neurotransmitter, and excessive release of glutamate may 
produce seizures, a reduction in glutamate release may reduce 
seizure activity and may affect epileptogenesis (Carlson 
et al 1992).
Interaction with other
neurotransmitters
Multiple studies have shown that zonisamide affects 
dopaminergic and serotonergic neurotransmission (Okada 
et al 1995, 1999; Kiryu et al 1997; Kawata et al 1999). In the 
rat hippocampus and striatum, zonisamide was noted to have 
a biphasic, dose-dependent effect on extracellular dopamine 
levels. At therapeutic zonisamide doses of 20–50 mg/kg, 
extracellular dopamine levels were increased; however, at 
higher doses ( 100      mg/kg), dopamine levels were decreased. 
Okada and colleagues (1999) suggested that this effect may 
account for the antiseizure and mood-stabilizing effects of 
zonisamide, as well as the adverse effect of sedation (Okada 
et al 1995). Zonisamide was reported to have a similar 
biphasic effect on serotonin levels in the rat hippocampus 
that was also dose-dependent. Again, it was thought that 
these effects may be involved with the antiseizure effects of 
zonisamide, as well as with positive psychotropic effects, 
such as improvements in bipolar and schizophrenic manic 
states (Okada et al 1999).
Free radical scavenging 
and neuroprotective effects
Current research has associated free radical damage with 
epilepsy (Komatsu et al 1995; Sudha et al 2001), and 
the use of antioxidants early in the treatment of seizure-
precipitating injuries is an attractive prevention target 
(Schwartzkroin 2004). Several studies have shown that 
the mechanism of antiepileptic effects of zonisamide may 
involve protection of neurons from free-radical damage by 
scavenging hydroxyl and nitric oxide radicals in a dose-
dependent manner (Mori et al 1998, 2004; Noda et al 1999). 
Zonisamide has also been reported to have free-radical 
scavenging activity and an inhibitory effect on lipid peroxide 
formation in rats with iron-induced epileptogenic foci 
(Komatsu et al 1995). In addition, the inhibition of excessive 
glutamate release following ischemic insult has been shown 
to protect against glutamate-induced neuronal damage in 
gerbils (Owen et al 1997). Another neuroprotective effect 
of zonisamide, unrelated to its anticonvulsant activity, was 
noted by Hayakawa et al (1994). In that study, a reduction in 
hypoxic-ischemic brain damage in neonatal rats was observed 
with zonisamide treatment; however, the exact mechanism 
by which the drug exerted this effect is unknown.
Pharmacokinetics (PK)
Population PK parameters were used for determining dose 
regimens in epileptic patients (Peters and Sorkin 1993; 
Hashimoto et al 1994; Kochak et al 1998). A favorable 
linear PK proﬁ  le has been reported for zonisamide, and the 
zonisamide parameters are summarized in Table 2.
PK proﬁ  le
The PK proﬁ  le of zonisamide has been well characterized. 
Zonisamide is rapidly and completely absorbed after oral 
administration. The time to maximal concentration (Tmax) 
following oral administration of 200–400 mg zonisamide 
is 2–6 hours and is slightly delayed with food intake at 
4–6 hours. The PK parameters of zonisamide are dose 
proportional with 200- to 400-mg dosing, but at 800-mg dosing 
and above, the area under the curve (AUC) and maximum 
plasma concentration (Cmax) increase disproportionately. It 
has been suggested that this disproportion occurs due to the 
saturation of red blood cells with zonisamide. With a stable main-
tenance dosage, steady state is usually achieved within 14 days 
(Peters and Sorkin 1993; Eisai Inc 2004; Leppik 2004).
Table 2 Pharmacokinetic proﬁ  le of zonisamide
Parameter Value
Tmax 2–6 h
Bioavailability  95%
Protein binding 40%
Elimination Renal
Elimination half-life 63 h
Elimination half-life after concurrent administration
of other AED(s)
 Phenytoin 27  h
  Phenobarbital, carbamazepine 38 h
 Valproate 46  h
Abbreviations: AED, antiepileptic drug; h, hour;   Tmax, time to maximal concentration.Neuropsychiatric Disease and Treatment 2006:2(3) 272
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Long half-life
Zonisamide is concentrated in red blood cells through car-
bonic anhydrase and protein binding. It is only 40% protein 
bound, which suggests a relatively low risk of protein-binding 
interactions with concomitant AEDs. The elimination half-
life of zonisamide in plasma is between 63 and 69 hours 
in healthy volunteers, and the elimination half-life in red 
blood cells is approximately 105 hours. The long half-life 
of zonisamide is a key advantage that enables a once-daily 
dose regimen and assures attainment of steady therapeutic 
drug levels. Even when zonisamide is given with isoenzyme-
inducing AEDs, its half-life remains above 24 hours (Kochak 
et al 1998; Leppik 1999; Eisai Inc 2004; Leppik 2004).
Metabolism
Hepatically metabolized through the cytochrome P450 
pathway by isoenzyme 3A4, zonisamide does not induce 
its own metabolism, nor does it induce liver enzymes. 
Concomitant AEDs may affect the PK of zonisamide by 
inducing liver isoenzymes at the cytochrome P450 path-
way, and may require dosage adjustments of zonisamide; 
however, zonisamide does not affect the PK of other AEDs 
(Eisai Inc 2004).
Zonisamide is metabolized via two major pathways. 
It undergoes acetylation to form N-acetyl zonisamide and 
reduction to form the open-ring metabolite 2-sulfamoylacetyl 
phenol (SMAP). The cytochrome P450 isoenzyme 3A4 
(CYP3A4) mediates reduction to SMAP. Unlike some 
AEDs, zonisamide does not produce any active metabolites. 
Unchanged zonisamide comprises about 35% of the excreted 
dose, which is excreted primarily in the urine (Stiff et al 1992; 
Nakasa et al 1993; Eisai Inc 2004).
Drug-drug interactions
Concomitant drugs that either induce or inhibit CYP3A4 
may alter serum concentrations of zonisamide. Concurrent 
administration of phenytoin and carbamazepine with 
zonisamide has been shown to increase zonisamide plasma 
clearance from 0.30 to 0.35  mL/min/kg to 0.35 to 0.5  mL/min/kg 
(Ragueneau-Majlessi et al 2004). The 63-hour elimination 
half-life of zonisamide has been reported to be decreased to 
27 hours by phenytoin, to 38 hours by phenobarbital and car-
bamazepine, and to 46 hours by valproate. Hence, when these 
AEDs are coadministered with zonisamide, therapeutic moni-
toring is necessary and dosage adjustments of zonisamide 
may be required. However, recent studies have reported 
that valproate does not affect the PK of zonisamide, and no 
dosage adjustment of either drug should be required when 
used together (Ragueneau-Majlessi et al 2005). Studies have 
also shown that concurrent administration of lamotrigine 
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Figure 2  Cytochrome P450 reduction and nonenzymic hydrolysis. Zonisamide is metabolized through two major pathways: (1) by reductive cleavage of the benzisoxazole 
ring of the parent drug by cytochrome P450 isoenzyme 3A4 (CYP3A4) to form 2-sulfamoylacetyl phenol (SMAP) and (2) by acetylation to form N-acetyl zonisamide. 
Reprinted from: Leppik IE. 2004. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure, 13(Suppl 1):S5–9. Copyright © 2004, with permission from 
BEA Trading Ltd.
Abbreviations: FMN, ﬂ  avin mononucleotide; SKF 525-A, inhibitor and inducer of cytochrome P450.Neuropsychiatric Disease and Treatment 2006:2(3) 273
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and zonisamide does not alter the steady-state PK of either 
drug, also demonstrating that no dosage adjustment is 
required (Levy et al 2005). Zonisamide does not alter the 
PK parameters of concomitant AEDs due to its low protein 
binding (Cloyd and Remmel 2000; Eisai Inc 2004).
Effects on oral contraceptives (OCs)
Unlike other AEDs, steady-state zonisamide dosing has 
been shown to have no signiﬁ  cant effect on the PK of a 
combination OC, speciﬁ  cally ethinyl estradiol (EE, 0.035 mg) 
and norethindrone (NOR, 1 mg), in healthy, premenopausal 
women aged 18–51 years (mean age 26.1 years). Addition-
ally, zonisamide did not increase concentrations of luteiniz-
ing hormone, follicle-stimulating hormone, or progesterone, 
which are indicators of contraceptive efﬁ  cacy. Hence, no 
pharmacodynamic evidence of zonisamide reducing the 
effectiveness of OCs containing EE or NOR has been docu-
mented (Grifﬁ  th and Dai 2004).
Safety
Zonisamide is generally safe and well tolerated for use in 
patients with epilepsy. The most commonly reported AEs 
associated with zonisamide use in controlled clinical trials 
were somnolence, anorexia, dizziness, headache, nausea, and 
agitation–irritation (Eisai Inc 2004).
Postmarketing studies conducted in Japan revealed that 
pediatric patients appear to be at an increased risk for oligohi-
drosis and hyperthermia in association with zonisamide use. 
Patients should be monitored closely for signs of decreased 
sweating and increased body temperature, especially in warm 
or hot weather (Eisai Inc 2004).
In some patients taking zonisamide, weight loss has been 
observed, in contrast to weight gain that is often observed 
in clinical studies of other AEDs. In a pivotal clinical study 
of zonisamide in 203 patients with refractory partial-onset 
seizures, weight loss of greater than 5 pounds was reported in 
21.6% of zonisamide-treated patients, while it was reported 
in only 10.4% of placebo-treated patients (p = 0.044) (Faught 
et al 2001).
Management of partial seizures
Since up to 30% of patients with epilepsy, speciﬁ  cally 
those with partial seizures, become refractory to treatment 
with standard AEDs, effective treatment for this group is of 
interest (Chadwick and Marson 2000). Extensive clinical 
data worldwide have shown that zonisamide is effective 
and well tolerated for the treatment of refractory partial 
seizures. In the USA and Europe, 22 Phase II/III studies of 
zonisamide have been conducted, including two controlled 
studies each in the USA and Europe. Three of these (two in 
the USA and one in Europe) were pivotal for US approval 
in evaluating the safety and effectiveness of adjunctive 
zonisamide in a total of 493 adult patients with refractory 
partial seizures who were receiving one or two other AEDs 
(Schmidt et al 1993; Faught et al 2001; Sackellares et al 
2004). These were all double-blind, randomized, parallel-
group, placebo-controlled, multicenter studies. Efﬁ  cacy 
results for these studies, including the median percentage 
reduction in partial seizures and percentage of responders 
(ie, patients having  50% seizure reduction), are presented 
in Table 3 (Eisai Inc 2004). A more recent investigation into 
the effectiveness and tolerability of adjunctive zonisamide, 
as well as their dose-response relationship, was conducted in 
a large cohort of patients with epilepsy (Brodie 2005). These 
four studies are described in detail below.
Schmidt et al 1993
Schmidt et al (1993) conducted a European placebo-
controlled, double-blind study in 139 patients with partial 
epilepsy. All enrolled patients were previously receiving one 
Table 3 Median percentage reduction in all partial seizures and percentage responders in primary efﬁ  cacy analyses: intent-to-treat 
analysis
Study Median % reduction
in partial seizures % Respondersa
 Zonisamide Placebo Zonisamide Placebo
Faught et al 2001
Weeks 8–12
n = 98
40.5b
n = 72
9.0
n = 98
41.8b
n = 72
22.2
Sackellares et al 2004 
Weeks 5–12
n = 69
29.6b
n = 72
−3.2
n = 69
29.0
n = 72
15.0
Schmidt et al 1993
Weeks 5–12
n = 67
27.2b
n = 66
−1.1
n = 67
28.0b
n = 66
12.0
aResponders are patients with  50% reduction in partial seizure frequency.
bp   0.05 compared with placebo.Neuropsychiatric Disease and Treatment 2006:2(3) 274
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to three AEDs, such as carbamazepine, phenobarbital, 
phenytoin, and primidone. The median frequency reduction 
for all partial seizures (eg, complex and simple) was signiﬁ  -
cantly higher for patients taking zonisamide (26.9%) than for 
the placebo group (p   0.05), who experienced a 3.9% median 
increase. For simple partial seizures, zonisamide-treated 
patients experienced a higher median seizure frequency 
reduction (72.6%) than did placebo-treated patients (48.1%). 
For all partial seizures, 30.3% of zonisamide-treated patients 
experienced a greater than 50% reduction, while 10.9% of 
placebo-treated patients reported the same effect (p   0.05). 
For generalized and partial seizures, 29.9% and 9.4% of 
patients on zonisamide and placebo, respectively, were con-
sidered responders (p   0.05). Fifty-nine percent and 27.9% 
of zonisamide- and placebo-treated patients experienced 
AEs, respectively. The most common AEs included fatigue, 
somnolence, and dizziness (Schmidt et al 1993).
Faught et al 2001
Faught and colleagues (2001) conducted a dose-response 
study of adjunctive zonisamide in 203 patients with 
refractory partial seizures, 146 (72%) of whom completed 
the 5-month study. The study included patients who 
were receiving one or two standard AEDs consisting of 
carbamazepine, phenobarbital, phenytoin, primidone, or 
valproic acid. After the baseline phase, zonisamide was 
titrated to a daily dose of zonisamide 400 mg at three stag-
gered titration rates. Efﬁ  cacy and safety were evaluated at 
zonisamide dosages of 100, 200, and 400 mg/day. Efﬁ  cacy 
(change in seizure frequency from weeks 8 to 12 compared 
with baseline) was reported to be comparable between 
zonisamide daily dosages of 100 and 200 mg, with a median 
reduction in seizure frequency of 24.7% for the zonisamide 
group compared with 8.3% for the placebo group (100-mg/
day dose) and 20.4% for zonisamide versus 4.0% for placebo 
(200-mg/day dose). The median seizure frequency reduction 
was 40.5% for patients receiving zonisamide 400 mg/day, 
and 9.0% for placebo-treated patients (p = 0.009). The differ-
ence in efﬁ  cacy observed between low and high dosages of 
zonisamide suggested a dose-response effect (Table 4). For 
all zonisamide dosages, the number of zonisamide-treated 
patients who were responders (ie, had  50% seizure fre-
quency reduction) was signiﬁ  cantly greater than that reported 
for placebo-treated patients (p   0.05, Table 4). Adverse 
events of somnolence, anorexia, and rhinitis were reported 
most frequently, and occurred at a slightly higher incidence 
with zonisamide than placebo. Weight loss was the only 
AE with a signiﬁ  cantly higher incidence rate in zonisamide-
treated patients (21.6%) compared with patients on placebo 
(10.4%, p = 0.044). The percentage of patients who discon-
tinued treatment due to AEs while on zonisamide therapy 
(10%) was comparable to those on placebo (8.2%, p = NS). 
Overall, most AEs were mild to moderate and declined with 
time (Faught et al 2001).
Sackellares et al 2004
In the study reported by Sackellares and colleagues (2004), 
152 patients (age range 18–68 years, mean 36 years) who 
were receiving one to two AEDs, such as carbamazepine, 
phenobarbital, phenytoin, and primidone were randomized 
to either a maximum zonisamide dosage of 400–500 mg/day 
(given twice daily) or placebo. Of these, 131 patients 
completed treatment at week 12, including 64 patients 
(82.1%) in the zonisamide group and 67 patients (90.5%) 
Table 4 Median percentage reduction in all partial seizures and percentage responders for dose analysis in Faught et al 2001: intent-to-treat 
analysis
Dose group Median % reduction
in partial seizures % Respondersa
Zonisamide Placebo Zonisamide Placebo
100–400 mg/day n = 112 n = 83 n = 112 n = 83
Weeks 1–12 32.3b 5.6 32.1b 9.6
100 mg/day n = 56 n = 80 n = 56 n = 80
Weeks 1–5 24.7b 8.3 25.0 11.3
200 mg/day n = 55 n = 82 n = 55 n = 82
Weeks 2–6 20.4b 4.0 25.5b 9.8
400 mg/day n = 98 n = 72 n = 98 n = 72
Weeks 8–12 40.5b 9.0 41.8b 22.2
aResponders are patients with   50% reduction in partial seizure frequency.
bp   0.05 compared with placebo.Neuropsychiatric Disease and Treatment 2006:2(3) 275
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in the placebo group. A 28.9% reduction in partial seizure 
frequency was reported for the zonisamide group, while a 
4.7% increase in partial seizure activity was reported for 
the placebo group (p = 0.0009). The zonisamide group had 
a greater percentage of responders: 26.9% compared with 
16.2% for the placebo group (p = 0.1141). On the basis of 
patient and physician global assessments, more patients on 
zonisamide were rated as improved compared with placebo. 
The most common AEs were somnolence, irritability, and 
dizziness. During this study, the authors determined that 
a slower titration of zonisamide (100 mg/day Week 1, 
200 mg/day Week 2, 400 mg/day Week 3 versus starting at 
400 mg/day) was associated with fewer AEs (Sackellares 
et al 2004).
Brodie et al 2005
In a double-blind, placebo-controlled, dose-response study, 
351 patients with refractory partial seizures on a stable 
regimen of one to three AEDs were randomized to placebo 
or zonisamide 100, 300, or 500 mg/day. Patients (efﬁ  cacy-
analysis population) given zonisamide 300 and 500 mg/day 
experienced a signiﬁ  cantly greater median reduction in 
frequency of all partial seizures (complex and simple) than 
did placebo-treated patients (zonisamide 300  mg/day, 46.4% 
[p = 0.0007 vs placebo]; zonisamide 500 mg/day, 50.6% 
[p   0.0001 vs placebo]; placebo, 19.4%; efﬁ  cacy-analysis 
population). The median reduction in frequency of all partial 
seizures in zonisamide-treated patients at 100 mg/day was 
similar to placebo. In addition, the percentage of responders 
for all partial seizures was higher for all zonisamide groups 
(500 mg, 50.5%; 300 mg, 42.9%; 100 mg, 28.8%) compared 
with placebo (20.2%), with a statistically signiﬁ  cant treat-
ment difference between the 500-mg/day group and placebo 
(p   0.001). In this study, and in the 2001 US study (Faught 
et al 2001), a signiﬁ  cant dose-response relationship was 
observed with all seizure types (p   0.0001). The most 
frequent AEs were somnolence, headache, and dizziness 
(Brodie et al 2005). The results presented in this study were 
pivotal for approval of zonisamide use in Europe.
Clinical applications of zonisamide
Pediatric patients
Many AEDs do not have indications for pediatric use, yet 
these agents are commonly used in pediatric epilepsy. In 
the US, while zonisamide is not approved for use in pedi-
atric patients, data are accumulating from its clinical use 
in children. One open-label chart review completed in the 
US evaluated 50 charts of pediatric patients with epilepsy 
(mean age, 9.1 years; age range, 9 months to 20 years) who 
were on zonisamide therapy (Santos and Brotherton 2005). 
Three patients were taking zonisamide as monotherapy, the 
remainder of the patients as adjunctive therapy; lamotrigine 
and valproate were the most common concomitant AEDs. 
Prior to treatment, the children averaged three to four 
seizures per week. The mean daily dose of zonisamide was 
15.8 mg/kg or 412 mg. At the end of treatment, 8 patients 
(16.0%) were seizure free, and 11 (22.0%) were responders 
to treatment with greater than 50% reduction; of these 
patients, 11 (22.0%) were previously unsuccessfully treated 
while on 6 or more AEDs. Antiseizure activity for seizure-
free patients and responders was reported to occur within 
the ﬁ  rst 2 weeks of treatment. Eleven patients (22.0%) 
had less than 50% seizure reduction. Thirty-one patients 
(62.0%) experienced at least one AE; 14 discontinued treat-
ment due to an AE. The most frequently reported AEs were 
reduction in appetite (28.0%), weight loss (10.0%), and 
increased phenytoin levels in patients concurrently taking 
phenytoin (10.0%).
Juvenile myoclonic epilepsy (JME)
Juvenile myoclonic epilepsy is found in 5%–11% of all 
patients with epilepsy, and it possesses multiple seizure 
types, including myoclonic, generalized tonic-clonic, 
and absence. Valproate is currently recommended as the 
drug of choice in treating JME. With the knowledge of 
zonisamide’s broad spectrum of antiepileptic effects, sev-
eral retrospective studies have been conducted to assess the 
efﬁ  cacy and safety of zonisamide as a treatment for JME. 
In a study by Kothare and colleagues (2004), 15 patients 
aged 11–20 years who were diagnosed with JME and 
treated with zonisamide were identiﬁ  ed. Patients received 
zonisamide 200–500 mg/day for a mean follow-up period 
of 12 months (range, 2–24 months); 2 patients were given 
zonisamide adjunctively, with the remainder of the patients 
on zonisamide monotherapy. Eighty percent of patients 
on zonisamide monotherapy experienced 50% or greater 
seizure frequency reduction. Seizure freedom was achieved 
with 69%, 62%, and 38% of patients for generalized tonic-
clonic, myoclonic, and absence seizures, respectively. One 
patient on adjunctive therapy experienced a greater than 
75% seizure reduction, while another patient showed no 
effect. Three patients (20.0%) experienced AEs, includ-
ing weight loss, headache, and dizziness, which resolved 
with maintenance (Wallace 1998; Kothare et al 2004). 
A retrospective study conducted by Welty and colleagues 
(2004) also showed that zonisamide may be effective Neuropsychiatric Disease and Treatment 2006:2(3) 276
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for JME. In this chart review, the efﬁ  cacy and safety 
of zonisamide were examined in 36 patients on various 
AEDs (eg, lamotrigine, topiramate, levetiracetam, and 
zonisamide). The authors concluded that zonisamide was 
associated with a decrease in frequency of myoclonic, 
generalized tonic-clonic, and absence seizures, which are 
all characteristic of JME. They also noted that the use of 
zonisamide allowed for the discontinuation of concomitant 
valproate (Welty 2004).
Absence seizures
Wilfong and Schultz (2005) conducted a chart review of 
45 patients (mean age, 11.4 years; range, 2.8–17.9 years) 
with absence seizures to assess the effectiveness and safety 
of zonisamide in absence epilepsy. Patients received a mean 
daily dose of zonisamide 343 mg or 9.0 mg/kg (range, 
100–600 mg or 2–24 mg/kg). Twenty-three of 45 patients 
(51.1%) obtained seizure freedom, while 16 of 45 patients 
(35.6%) experienced 50% or greater seizure reduction. Five 
patients (11.1%) had less than 50% seizure reduction, while 
one patient (2.2%) had an increase in seizure frequency. 
Nineteen patients (42.2%) reported one or more AEs, with 
decreased appetite (15.5%) and sleepiness (11.1%) being 
the most common. Two patients discontinued zonisamide 
therapy due to an increase in seizure frequency for one, and 
apparent inefﬁ  cacy and sleepiness in the other.
The Japanese experience
Zonisamide is approved for use with pediatric patients in 
Japan and has consequently been used extensively in children 
by physicians and in controlled clinical studies. Japanese 
clinical and postmarketing data have demonstrated that 
zonisamide adjunctive and monotherapy is efﬁ  cacious and 
well tolerated in children with various epileptic syndromes, 
as well as in adults.
In a Japanese PK and efﬁ  cacy study, zonisamide mono-
therapy as once-daily dosing was investigated in 72 pediatric 
patients aged 3 months to 15 years (mean, 8 years and 
3 months). These patients were diagnosed with cryptogenic 
localization-related epilepsy with partial seizures and had 
not received prior treatment for epilepsy. Zonisamide was 
started at a daily dosage of 2 mg/kg and was doubled each 
week to obtain a maintenance dosage (mean, 7.97 mg/kg). 
Seizure control was achieved in 57 of the 72 patients 
(79.2%). The therapeutic range for zonisamide plasma levels 
for these pediatric patients was found to be 15–40 μg/mL. 
Peak-to-trough ratios were small (mean, 1.28; SD 0.15), 
similar to those observed in healthy adult volunteers 
(Kochack et al 1998). There was no clear relationship 
between zonisamide plasma levels and seizure control. For 
patients with less than 50% seizure reduction, the addition 
of carbamazepine to the drug regimen helped seizure control 
with limited success. Overall, this study demonstrated that 
zonisamide can provide effective control as monotherapy in 
pediatric patients. The authors recommended that age and 
weight be taken into consideration for the initial maintenance 
dose, because ratios of plasma zonisamide levels to dose 
increase with age (Miura 2004).
In 2002, 20 Japanese pediatric clinical trials were summa-
rized and analyzed in a review of the Japanese postmarketing 
experience. Fourteen of these trials were predominately open-
label assessments of the efﬁ  cacy and safety of zonisamide for 
the treatment of partial- and generalized-onset seizures. The 
remainder of the trials evaluated zonisamide use in children 
with Lennox-Gastaut syndrome (LGS) or infantile spasms 
(IS) (Glauser and Pellock 2002).
In the ﬁ  ve open-label trials of zonisamide as adjunc-
tive therapy in pediatric patients with partial- and 
generalized-onset seizures, 34% and 15% of children 
with partial and generalized seizures, respectively, were 
considered responders to zonisamide at a daily dosage 
of 0.7–18.6 mg/kg, or where not reported as mg/kg, at 
50–600 mg. In ﬁ  ve trials that examined zonisamide mono-
therapy, data from 209 pediatric patients with partial sei-
zures and 49 patients with generalized-onset seizures were 
analyzed. Results indicated that 78% of patients (164/209) 
with partial seizures and 71% of patients (35/49) with 
generalized-onset seizures were responders to zonisamide 
monotherapy at daily dosages of 1–12 mg/kg (Glauser and 
Pellock 2002).
Five small, open-label studies assessed the efﬁ  cacy of 
zonisamide adjunctive therapy in a total of 64 children 
with IS. In these studies, the number of patients reported 
as responders ranged from 22% (2/9) to 36% (8/22). A few 
studies of zonisamide have been performed in children with 
LGS as well, with reports of 26% (10/39) to 50% (10/20) 
of patients being responders to zonisamide (Glauser and 
Pellock 2002).
In these Japanese pediatric postmarketing studies, 
the most commonly reported AE was somnolence. The 
AEs were generally mild to moderate in severity, were 
similar to those seen in adults, and were typical of other 
AEDs. The incidence of AEs was greater with increasing 
zonisamide dosage and concomitant AEDs in use. Resolu-
tion of most AEs was reported to occur with adjustments 
of dosage or drug regimen. Zonisamide was best tolerated Neuropsychiatric Disease and Treatment 2006:2(3) 277
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in children when the daily dosage was increased in small 
increments of 0.5–1.0 mg/kg every 2 weeks (Glauser and 
Pellock 2002). Overall, clinical experience in Japan has 
demonstrated that zonisamide is safe and well tolerated 
in children with various seizure disorders and epileptic 
syndromes.
Zonisamide as monotherapy
Published literature has reported that monotherapy, if 
effective, is a more attractive option for patients with 
epilepsy than adjunctive therapy, although this goal is 
often not realized. Monotherapy prevents drug-drug inter-
actions with other AEDs, reduces the incidence of AEs, 
and improves patient compliance. Short- and long-term 
efﬁ  cacy of zonisamide as monotherapy for epilepsy has 
been investigated in the USA and Japan. In one Japanese 
study, zonisamide as monotherapy was assessed for up to 
5 years in 77 pediatric patients aged 8 months to 15 years. 
Nine patients were withdrawn due to AEs and were not 
included in the efﬁ  cacy analysis, but were included in the 
assessment of AEs. Patients were administered zonisamide 
at a daily dosage of 2–12 mg/kg. In general, both patients 
with partial seizures and patients with generalized seizures 
were responders to zonisamide therapy. Patients who 
were seizure–free or responders ( 50% seizure reduction) 
to zonisamide therapy tended to have a longer duration 
exposure to zonisamide (mean, 1.75 years) compared with 
nonresponders ( 50% seizure reduction; mean, 4 months). 
Thirty patients (39.0%) reported AEs, including somnolence 
(11.7%), reduction in spontaneity (7.8%), anorexia (6.5%), 
and rash (6.5%) (Seki et al 2004).
In 2004, a Japanese prospective postmarketing study 
investigated the long-term effectiveness of zonisamide 
in over 1600 pediatric and adult patients with partial 
and generalized epilepsy. Results of this study indicated 
that zonisamide was significantly effective in treating 
idiopathic generalized epilepsy and treating partial epi-
lepsy, with 78% and 58% of patients reporting seizure 
improvement (ie,  50% reduction in seizure frequency), 
respectively. In addition, more than 50% of patients with 
myoclonic and atypical absence seizures and 28% of 
patients with West syndrome or LGS showed improve-
ments with zonisamide therapy. The authors of the 
postmarketing study found that patients on zonisamide 
monotherapy had greater improvement than patients 
on polytherapy (Yamauchi and Aikawa 2004). Overall, 
the efficacy of long-term use of zonisamide was main-
tained and was significantly effective against partial and 
generalized seizures, while showing promise for the treat-
ment of other epilepsies.
The long-term effects of zonisamide as monotherapy 
were also assessed by Fukushima and Seino (2004) in a 
Japanese database survey. More than 790 patients with 
epilepsy were treated with zonisamide as adjunctive or 
monotherapy; 51 adults and children (24 males, 27 females) 
were selected for analysis. In this study, partial seizures, 
generalized seizures, drop attacks (ie, atonic seizures), 
atypical absence seizures, myoclonic seizures, and LGS 
were shown to be effectively controlled with zonisamide. 
Thirty-eight patients continued zonisamide monotherapy, 
but 13 patients discontinued zonisamide due to lack 
of efﬁ  cacy (n = 10), restlessness and insomnia (n = 2), 
and failure to take zonisamide (n = 1) (Fukushima and 
Seino 2004).
In a recent US chart review study of pediatric and young 
adult patients with a range of seizure types, 131 patients 
aged 1–22 years using zonisamide as monotherapy 
were evaluated via seizure diaries and patient subjective 
assessments of efﬁ  cacy. Patients were given a median 
maintenance dosage of zonisamide 260 mg/day (range, 
100–800 mg/day). Of the 131 patients, 101 (77.1%) 
achieved a 50% or greater reduction in seizure frequency, 
and 39 (29.8%) were seizure free. The percentage of patients 
in each age group who achieved seizure freedom is shown 
in Figure 3. Forty-three patients (32.8%) experienced at 
least one AE, with decreased appetite (9.2%), weight loss 
(6.9%), sleeplessness (5.3%), and sedation (3.8%) as the 
most common AEs. Only three patients (2.3%) discontinued 
due to an AE, speciﬁ  cally for sleeplessness and increased 
seizure frequency, failure to gain weight, and behavioral 
changes (Wilfong 2005).
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Catastrophic epilepsies of childhood
Catastrophic epilepsies, such as progressive myoclonic epi-
lepsy (PME) and IS pose a signiﬁ  cant treatment challenge. 
Many patients with catastrophic epilepsies are refractory to 
standard AED treatment. Further, the occurrence of multiple 
seizure types in patients with these epilepsies complicates 
treatment, as one AED may decrease the occurrence of one 
seizure type while exacerbating another type (Conry 2004). 
Zonisamide has shown promise as an effective treatment 
for these childhood epilepsies, as described in the follow-
ing studies.
Progressive myoclonic epilepsy (PME)
Etiologically categorized into multiple subtypes, PME is 
characterized by progressive neurodegeneration and myo-
clonic seizures. Myoclonic seizures are difﬁ  cult to classify 
since they may be focal or regional, rhythmic or arrhythmic, 
small or massive contractions, and they can occur unilaterally 
or bilaterally. In addition, patients with PME often present 
with other seizure types, including generalized tonic-clonic, 
absence, and partial seizures (Leppik 2003). Treatment of 
seizures in patients with PME is complicated and determining 
efﬁ  cacy is confounded by a multitude of factors, such as the 
progression of the PME (Conry 2004). As PME progresses, 
myoclonic seizures may debilitate the patients, as normal 
daily activities, such as eating and drinking, become more 
challenging (Leppik 2003).
Progressive myoclonic epilepsy can be divided into 
severe myoclonic epilepsy syndromes of infancy and child-
hood, or the less severe progressive PMEs of juvenile or 
adult onset. There are many different forms of PMEs but 
the most common type of PME is Unverricht-Lundborg 
disease (ULD), an autosomal recessive inherited disorder. 
The onset of ULD generally occurs between 8 and 13 years 
of age, with a late peak occurrence. The progression of this 
disease usually stabilizes at the age of 40. Lafora’s disease is 
another type of PME distinguished from ULD by dementia, 
fast progression, and intracellular inclusion bodies. Onset of 
Lafora’s disease occurs between the ages of 14 and 16 years, 
and patient survival usually does not exceed 12 years post-
onset (Leppik 2003).
Currently, valproate is the gold standard for treatment 
of PME; however, a potential for hepatic and pancreatic 
dysfunction requires constant monitoring of patients 
receiving such medication (Conry 2004). Recent studies 
have suggested the use of zonisamide for the treatment of 
PME (Henry et al 1988; Kyllerman and Ben-Menachem 
1998; Vossler and the Zonisamide PME Study Group 
2002; Leppik 2003; Conry 2004). Henry and colleagues 
(1988) reported that two patients with PME had a marked 
reduction in seizure frequency and signiﬁ  cant improve-
ments after treatment with zonisamide, including normal 
speech and improved short-term memory and ataxia. In a 
case study by Kyllerman and Ben-Menachem (1998), ﬁ  ve 
patients with ULD and one patient with Lafora’s disease 
(ages 19–42 years) were evaluated for a follow-up period 
of 2–3 years after receiving a daily dose of zonisamide of 
100–600 mg with concomitant AEDs, such as valproate 
and benzodiazepine. A dramatic reduction in myoclonic 
and generalized seizures was obtained with zonisamide in 
all patients; however, in 3 patients, the antiseizure effect on 
myclonic seizures was absent after 2–4 years of treatment 
(Kyllerman and Ben-Menachem 1998).
One open-label study of zonisamide was performed 
with 30 patients with PME (mean age, 18.4 years; range, 
4–41 years). Ten patients (33.3%) discontinued treatment 
due to AEs (n = 5), noncompliance–selection criteria (n = 3), 
inefﬁ  cacy of treatment (n = 1), and no test conﬁ  rming PME 
(n = 1). Fifteen patients counted myoclonic seizures either 
in 10-minute periods in the morning, afternoon, and evening, 
while 8 patients counted myoclonic seizures over 24-hour 
periods. Forty percent of patients with the 10-minute counts 
and 50% of patients with the 24-hour counts experienced 
greater than 50% reduction in seizure frequency. Global 
assessments from investigators revealed patient improve-
ment as well. The most common AEs were anorexia (26.7%), 
somnolence (23.3%), and asthenia (23.3%) (Vossler and the 
Zonisamide PME Study Group 2002).
Infantile spasms (IS)
IS are present in childhood and are characterized by a 
distinct electroencephalographic (EEG) pattern of hyp-
sarrhythmia. IS etiologically are categorized into two 
broad yet distinct subtypes, cryptogenic and symptom-
atic, deﬁ  ned by the absence or presence of an underlying 
cause or neurologic abnormality. Cryptogenic spasms 
have no identiﬁ  able cause, no evidence of brain-imaging 
abnormalities, and normal development before the onset 
of seizures. Approximately 10%–15% of patients with IS 
have a cryptogenic etiology. Symptomatic patients have 
deﬁ  nable abnormalities and often have poor outcomes, with 
less than 5% displaying normal neurodevelopment. Cur-
rently, corticosteroids and vigabatrin are used for treating 
IS; however, they are often associated with serious adverse 
effects, such as cushingoid facies, immunosuppresion, and 
retinopathy (Conry 2004).Neuropsychiatric Disease and Treatment 2006:2(3) 279
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Recently, zonisamide has been suggested as a treatment 
option for IS. In one study, 23 patients with symptomatic 
IS were treated with zonisamide for a mean duration of 
6.5 months. Patients received a mean maximum zonisamide 
daily dosage of 18 mg/kg (range, 8–32 mg/kg). Of the 
23 patients, 6 (26.1%) were spasm free and showed clearing 
of EEG abnormalities, speciﬁ  cally hypsarrhythmia, which 
occurred at a mean of 19 days after the introduction of 
zonisamide. No patients discontinued treatment due to AEs 
(Lotze and Wilfong 2004). A chart review study completed 
by Wilfong (2005) evaluating zonisamide monotherapy for 
epilepsy in children and adults included 9 subjects diagnosed 
with IS. Five of these patients (55.6%) became seizure free 
and three subjects (33.3%) reported 75% or greater decrease 
in seizure frequency while on zonisamide monotherapy. 
These results were similar to those of a Japanese study that 
assessed the efﬁ  cacy of zonisamide in 11 patients with IS 
(Suzuki et al 1997).
Discussion
Spanning a period of 31 years, preclinical and clinical 
experience with zonisamide has established the drug as a 
broad-spectrum antiepileptic agent. Zonisamide has provided 
immense beneﬁ  ts for those afﬂ  icted with various seizure 
disorders. Its multiple mechanisms of action are consistent 
with antiseizure activity reported in the clinical studies of 
zonisamide. Zonisamide was well tolerated and effective 
even in patients with absence epilepsy and catastrophic epi-
leptic disorders, such as myoclonic epilepsy and IS, which 
warrant a universal treatment.
Zonisamide has a PK proﬁ  le that is ideal with its long 
half-life, which allows for once-daily dosing. It has shown 
efﬁ  cacy as monotherapy, thus possibly improving patient 
compliance. Additionally, zonisamide does not affect the 
PK of concomitant drugs, including AEDs and OCs, which 
is advantageous for adjunctive therapy.
Japanese experience with zonisamide therapy for the 
treatment of pediatric patients with refractory epilepsy illus-
trates that zonisamide is effective and well tolerated for long 
periods of time in children. In addition, extensive clinical and 
postmarketing data from Japan demonstrates that zonisamide 
as monotherapy is effective and safe in both pediatric and 
adult patients with epilepsy. However, additional controlled 
pediatric studies of zonisamide as monotherapy are warranted 
in the USA. Overall, positive experience with zonisamide 
as monotherapy in Japanese pediatric patients has further 
demonstrated the need for an adequate treatment for US 
children with refractory seizures.
In summary, zonisamide, as adjunctive therapy, and 
potentially as monotherapy, is successful in treating patients 
with refractory partial seizures because of its favorable PK 
proﬁ  le, unique structural and mechanistic proﬁ  le, safety, 
tolerability, and wide spectrum of antiseizure activity.
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